Table 1A:
Baseline demographic and clinical characteristics of all patients enrolled in the extra-pancreatic NET cohort
| Cabozantinib (n=134) | Placebo (n=69) | |
|---|---|---|
| Age, years, median (range) | 66 (28–86) | 66 (30–82) |
| Female Sex, n (%) | 74 (55) | 31 (45) |
| ECOG PS, n (%) | ||
| 0 | 49 (37) | 32 (46) |
| 1 | 84 (63) | 36 (52) |
| Primary tumor site, n (%)* | ||
| Gastrointestinal | 70 (52) | 46 (67) |
| Lung | 27 (20) | 12 (17) |
| Thymus | 6 (5) | 4 (6) |
| Unknown | 22 (16) | 2 (3) |
| Tumor grade, n (%) | ||
| Grade 1 | 37 (28) | 15 (22) |
| Grade 2 | 86 (64) | 48 (70) |
| Grade 3 | 8 (6) | 5 (7) |
| Unknown | 3 (2) | 1 (1) |
| Hormone syndrome present (functional tumor), n (%) | 41 (31) | 25 (36) |
| Concurrent SSA, n (%) | 92 (69) | 48 (70) |
| Number of prior systemic therapies not including SSA, median (range) | 2 (1–6) | 2 (1–6) |
| Prior systemic therapy, n (%) | ||
| SSA, n (%) | 125 (93) | 64 (93) |
| Lu-177 dotatate | 80 (60) | 41 (59) |
| Everolimus | 96 (72) | 44 (64) |
| Temozolomide +/− Capecitabine | 43 (32) | 20 (29) |
| Cisplatin or carboplatin + etoposide | 11 (8) | 8 (12) |
Abbreviations: ECOG PS: Eastern Cooperative Oncology Group Performance Status
*
The intent-to-treat cohort includes 7 patients with pancreatic neuroendocrine tumors (4 in the cabozantinib group and 3 in the placebo group) who were misallocated to the extra-pancreatic neuroendocrine tumor cohort by the registering site.